Furthermore, it discusses the evolving role of immune checkpoint inhibitors (ICIs) [6,7,8] and BRAF-targeted therapies in HCC treatment, highlighting their potential benefits and challenges in this context [9,10]. The gene discussed is BRAF; the disease is hepatocellular carcinoma.